Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Two series of MEK/c-Src kinase inhibitors claimed by AstraZeneca

June 29, 2004

New antiangiogenic agents in early development at Bayer

June 28, 2004

New phase II study of talabostat in CLL

June 28, 2004

Positive interim results from phase II trial of FK-228 in CTCL and PTCL

June 28, 2004

Synthetic adrenal steroid hormones protect from chemotherapy or radiation-induced myelodepression

June 28, 2004

Merck & Co. and Vertex collaborate on development of VX-680

June 28, 2004

CuraGen and Seattle Genetics sign ADC technology agreement

June 28, 2004

Safety issues associated with Pivanex plus docetaxel in phase IIb study

June 28, 2004

New antitumor agents developed by Sanofi-Synthelabo scientists

June 25, 2004

Roche claims two series of protein kinase inhibitors for use in cancer therapy

June 25, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.